合肥美亚光电技术股份有限公司 信息披露暂缓与豁免管理制度 第一章 总则 第一条 为规范合肥美亚光电技术股份有限公司（以下简称"公司"）和其 他信息披露义务人信息披露暂缓、豁免行为，加强信息披露监管，保护投资者合 法权益，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市 公司信息披露管理办法》、《上市公司信息披露暂缓与豁免管理规定》、《深圳 证券交易所上市公司自律监管指引第 5 号——信息披露事务管理》、《深圳证 券交易所股票上市规则》（以下简称"《上市规则》"）及《合肥美亚光电技术 股份有限公司章程》（以下简称"《公司章程》"）、《合肥美亚光电技术股份 有限公司信息披露管理制度 》等有关规定，结合公司实际情况，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证券监督管理委员会（以下简称"中国证监会"）和深 圳证券交易所（以下简称"深交所"）规定或者要求披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地 披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得实 施内幕交易、操纵市场等违 ...

合肥美亚光电技术股份有限公司 职工代表董事选任制度 第一章 总则 第一条 为规范合肥美亚光电技术股份有限公司（以下简称"公司"）的职 工代表董事选任流程，推动完善公司法人治理结构，根据《中华人民共和国公司 法》（以下简称"《公司法》"）《中华人民共和国工会法》及其他相关法律、 法规、规章、规范性文件和《合肥美亚光电技术股份有限公司章程》（以下简称 "《公司章程》"）的规定，特制定本制度。 第二条 职工代表董事是指按照《公司章程》确定的人数，由公司职工大会 或者职工代表大会民主选举产生，进入董事会，代表职工参与公司决策和监督的 董事。 第三条 职工代表董事的选任与管理，遵循以下原则： (一)依法合规原则； (二)民主选举原则； (三)公平、公正、公开原则； (四)职工代表性与董事会专业性相结合原则。 （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩 序，被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾五年，被宣告缓刑 的， 自缓刑考验期满之日起未逾二年； 第四条 本制度适用于公司职工代表董事的提名、选举、增补、更换（罢免） 及管理等事宜。 第二章 职 ...

合肥美亚光电技术股份有限公司 董事会审计委员会工作细则 第一章 总则 第一条 为强化合肥美亚光电技术股份有限公司(以下简称"公司")董事会 决策功能，做到事前审计、专业审计，确保董事会对经理层的有效监督，完善公 司治理结构，根据《中华人民共和国公司法》(以下简称"《公司法》")、《上 市公司治理准则》、《上市公司独立董事管理办法》、《合肥美亚光电技术股份 有限公司公司章程》（以下简称"《公司章程》"）等有关规定，公司董事会特 设立审计委员会，并制定本工作细则。 第二条 董事会审计委员会是董事会下设的专门工作机构，主要负责公司内、 外部审计的沟通、监督和核查工作。 第二章 人员组成 第三条 审计委员会成员由三名董事组成，其中独立董事两名(包括一名专业 会计人士)。 审计委员会成员应当为不在公司担任高级管理人员的董事。 第四条 审计委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一以上提名，并由董事会选举产生。 第五条 审计委员会设召集人一名，由会计专业独立董事担任，负责主持委 员会工作；召集人在委员内选举，并报请董事会批准产生。 第六条 审计委员会任期与董事会一致，委员任期届满，连选可以连任。期 ...

证券代码：002690 证券简称：美亚光电 公告编号：2025-026 合肥美亚光电技术股份有限公司 关于取消监事会并修订《公司章程》的公告 | 第一条 为维护合肥美亚光电技术股份 | 第一条 为维护合肥美亚光电技术股份 | | --- | --- | | 有限公司（以下简称"公司"）、股东 | 有限公司（以下简称"公司"）、股东、 | | 和债权人的合法权益，规范公司的组织 | 职工和债权人的合法权益，规范公司的 | | 和行为，根据《中华人民共和国公司法》 | 组织和行为，根据《中华人民共和国公 | | （以下简称《公司法》）、《中华人民 | 司法》（以下简称《公司法》）、《中 | | 共和国证券法》（以下简称《证券法》） | 华人民共和国证券法》（以下简称《证 | | 和其他有关规定，制订本章程。 | 券法》）和其他有关规定，制定本章程。 | | | 第八条 公司董事长为代表公司执行公 | | 第八条 董事长为公司的法定代表人。董 | 司事务的董事，并担任公司的法定代表 | | 事长辞任的，视为同时辞去法定代表 | | | | 人。董事长辞任的，视为同时辞去法定 | | 人。…… | 代表人。…… | ...

第五届董事会第十六次会议决议公告 证券代码：002690 证券简称：美亚光电 公告编号：2025-022 合肥美亚光电技术股份有限公司 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、董事会会议召开情况 合肥美亚光电技术股份有限公司（以下简称"美亚光电"或"公司"）于 2025 年 10 月 14 日以电话或电子邮件的方式发出召开第五届董事会第十六次会议的通知，会议于 2025 年 11 月 24 日上午 9:30 在公司会议室以现场和通讯的方式召开。本次会议应出席董 事 5 人，实际出席董事 5 人，会议由公司董事长田明先生主持。本次会议的召集、召开程 序均符合《公司法》和《公司章程》的有关规定。 二、 董事会会议审议情况 1、审议通过《2025 年第三季度报告》 表决结果：5 票同意，0 票反对，0 票弃权。 具 体 内 容 请 见 2025 年 10 月 25 日 刊 登 在 《 证 券 时 报 》 、 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上的公司《2025 年第三季度报告》。 2、审议通过《关于 2021 年限制性股 ...

证券之星消息，10月23日，美亚光电（002690）融资买入1278.3万元，融资偿还1051.55万元，融资净买 入226.76万元，融资余额1.79亿元，近3个交易日已连续净买入累计469.32万元。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-10-23 | 226.76万 | 1.79亿 | 2.03% | | 2025-10-22 | 140.32万 | 1.77亿 | 2.06% | | 2025-10-21 | 102.24万 | 1.75亿 | 2.05% | | 2025-10-20 | 244.24万 | 1.74亿 | 2.07% | | 2025-10-17 | -63.24万 | 1.72亿 | 2.01% | 融券方面，当日融券卖出600.0股，融券偿还100.0股，融券净卖出500.0股，融券余量5.79万股，近20个 交易日中有11个交易日出现融券净卖出。 | 交易日 | 融券冷卖出(股) | | 融券余量(股) | 融券余额(元) | | --- | --- | --- | -- ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index declined by 3.65% during the reporting period, ranking 21st among 31 primary industries, underperforming the CSI 300 index which fell by 2.73% [4][16] - The valuation of the pharmaceutical and biotechnology industry as of October 17, 2025, is a PE (TTM overall method, excluding negative values) of 30.08x, down from 31.23x in the previous period, indicating a downward trend and below the average [4][21] - Key sub-industries include vaccines (55.76x), hospitals (39.64x), and medical devices (38.84x), with the lowest valuation in pharmaceutical circulation (14.29x) [4][21] - The report highlights significant innovations presented at the 2025 ESMO conference, indicating a shift in global oncology drug development from "single-agent breakthroughs" to "combination therapy strategies" [6][8] - The newly released regulations by the State Council aim to standardize clinical research pathways, promoting innovation while ensuring safety [7][25][26] Industry Overview - The report notes that 26 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 501 million yuan, while 4 companies increased their holdings by 519 million yuan [4] - The report emphasizes the importance of monitoring third-quarter earnings to validate the fundamentals of companies, particularly those with innovative product launches and significant performance improvements [8] Important Industry News - The approval of the first domestic PDE4 inhibitor by He Mei Pharmaceutical marks a significant milestone in the industry [6][34] - The approval of a new indication for GSK's recombinant shingles vaccine expands its application to adults at increased risk due to immunodeficiency [6][36] - The U.S. Senate passed a revised version of the Biosecurity Act, which continues to impose restrictions on certain Chinese biotechnology companies [6][44] - The collaboration between Bai Li Tian Heng and BMS on the iza-bren project has reached a milestone, triggering a payment of 250 million USD [6][47] - The IPO of Xuan Zhu Biotechnology on the Hong Kong Stock Exchange saw a significant oversubscription and a substantial increase in share price during the dark trading period [6][49]

Core Viewpoint - Meiya Optoelectronics has shown a mixed performance in financing activities, with a slight increase in stock price but a net outflow in financing, indicating potential investor caution [1][2]. Financing Summary - On October 15, Meiya Optoelectronics experienced a stock price increase of 1.31%, with a trading volume of 79.43 million yuan. The financing buy-in amount was 5.63 million yuan, while the financing repayment was 9.11 million yuan, resulting in a net financing outflow of 3.48 million yuan [1]. - As of October 15, the total financing and securities lending balance for Meiya Optoelectronics was 176 million yuan, with the financing balance at 174 million yuan, accounting for 0.98% of the circulating market value, which is above the 80th percentile of the past year [1]. - In terms of securities lending, on the same day, 5,800 shares were repaid, and 1,300 shares were sold, amounting to a selling value of 26,200 yuan. The remaining securities lending volume was 63,500 shares, with a balance of 1.28 million yuan, which is below the 40th percentile of the past year [1]. Business Performance - For the first half of 2025, Meiya Optoelectronics reported a revenue of 1.02 billion yuan, reflecting a year-on-year growth of 9.92%. The net profit attributable to shareholders was 303 million yuan, marking an 11.34% increase compared to the previous year [2]. - The company's main business revenue composition includes 72.61% from color sorting machines, 19.97% from medical equipment, 5.25% from X-ray industrial inspection machines, and 2.17% from accessories and others [1]. Shareholder Information - As of October 10, the number of shareholders for Meiya Optoelectronics was 31,600, a decrease of 0.89% from the previous period. The average circulating shares per person increased by 0.90% to 13,738 shares [2]. - Cumulatively, since its A-share listing, Meiya Optoelectronics has distributed a total of 4.898 billion yuan in dividends, with 1.852 billion yuan distributed in the last three years [3]. - As of June 30, 2025, the second-largest circulating shareholder was Hong Kong Central Clearing Limited, holding 51.77 million shares, an increase of 8.18 million shares from the previous period. New shareholder 富国长期成长混合A (011037) entered as the ninth-largest shareholder with 5.0642 million shares [3].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 2.72%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which declined by 2.62% [4][16] - The industry valuation as of September 30, 2025, is a PE (TTM overall method, excluding negative values) of 31.23x, down from 31.79x in the previous period, indicating a downward trend and below the average [21] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (55.74x), medical devices (41.29x), and hospitals (39.51x), with the median at 33.19x, while pharmaceutical circulation has the lowest valuation at 14.34x [21] Industry Review - The report highlights that during the reporting period, 51 listed companies in the pharmaceutical and biotechnology sector had a net reduction in shareholders amounting to 2.435 billion yuan, with 14 companies increasing their holdings by 681 million yuan and 37 companies reducing their holdings by 3.116 billion yuan [4] - The report emphasizes the importance of upcoming clinical data and the strong fundamentals of companies ahead of the ESMO 2025 conference, which is expected to showcase significant clinical research results from various domestic pharmaceutical companies [7][8] Important Industry News - AstraZeneca plans to list on the New York Stock Exchange [6] - The report mentions the approval of a new oral SERD drug by Eli Lilly, marking it as the second such drug approved globally [8][45] - The approval of the first domestic quadrivalent HPV vaccine in China is expected to expand the coverage population and potentially be priced lower than imported versions [8][50][52]

Core Viewpoint - Meiya Optoelectronics has experienced a decrease in the number of shareholders for the second consecutive period, indicating a potential shift in investor sentiment [2] Shareholder Information - As of September 20, the number of shareholders for Meiya Optoelectronics was 31,321, a decrease of 2,080 from the previous period (September 10), representing a decline of 6.23% [2] - This marks the second consecutive decline in the number of shareholders [2] Stock Performance - The closing price of Meiya Optoelectronics on the reporting date was 21.99 yuan, reflecting an increase of 6.08% [2] - Since the concentration of shares began, the stock price has cumulatively increased by 10.06%, with 4 days of gains and 4 days of losses during this period [2] Financing Data - As of September 19, the margin trading balance for the stock was 181 million yuan, with a financing balance of 180 million yuan [2] - The financing balance has increased by 6.79 million yuan since the concentration of shares began, representing a growth of 3.92% [2] Financial Performance - In the first half of the year, Meiya Optoelectronics achieved operating revenue of 1.023 billion yuan, a year-on-year increase of 9.92% [2] - The net profit for the same period was 303 million yuan, reflecting a year-on-year growth of 11.34% [2] - The basic earnings per share were 0.3430 yuan, with a weighted average return on equity of 11.07% [2] Institutional Ratings - Over the past month, the stock has received buy ratings from 6 institutions [2] - The highest target price forecast is 25.60 yuan, as reported by Huatai Securities on August 26 [2]